Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 387.10%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.43, delivering a surprise of 4.44%.Over the last four quarters, ...

Table of Contents For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value Enhanced · Four potentially transformative Preclinical · Leading programs focus on iPSC- programs engineered with industry- derived 'tunable' CD4+/CD8+ aß T cells Pipeline leading Allo-Evasion™ 5.0 Selective expansion to non-immune . Century effector cells in high impact diseases Therapeutics: Concentrating clinical focus with CNTY-101 on autoimmune disorders with transformational Clear focus on potential Concentrate ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells and Allo-Evasion ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Century Therapeutics, Inc. (IPSC) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highligh ...

Core Viewpoint - Century Therapeutics, Inc. is advancing its preclinical cell therapy programs targeting autoimmune diseases and cancer, with a live event scheduled to discuss these developments [1][2]. Group 1: Company Overview - Century Therapeutics is a clinical-stage biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancers [4]. - The company aims to create off-the-shelf cell therapies to enhance patient access and improve treatment outcomes in autoimmune disease and cancer care [4]. Group 2: Upcoming Event Details - A live fireside chat will take place on April 22, 2025, at 10:00 a.m. EDT, where management will present details and data on prioritized preclinical programs [1]. - The event will cover investigational cell therapies including CNTY-308, a CD19-targeted CAR-iT therapy, and CNTY-341, a dual-targeted CAR-iT therapy, as well as a solid tumor CAR iT program [2]. - The discussion will highlight the proprietary immune evasion technology, Allo-Evasion™ 5.0, which aims to enable comprehensive evasion of various immune responses [2]. Group 3: Accessing Information - The live event can be accessed via the Investors page on Century's website, with a replay available for at least 30 days post-event [3].

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inve ...

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.44%. A quarter ago, it was expected that this company would post a loss of $0.46 per share when it actually produced a loss of $0.37, delivering a surprise of 19.57%.Over the last four quarters, the company ha ...

Clinical Trials and Efficacy - CNTY-101 is currently in Phase 1 trials targeting CD19 for B-cell malignancies and autoimmune disorders, with a focus on repeat dosing enabled by Allo-Evasion™ technology[22]. - The ELiPSE-1 study shows a median overall response rate (ORR) of 83% with a median follow-up of 2.9 months, indicating promising efficacy for CNTY-101[32]. - CNTY-101 demonstrated increased exposure and dose-responsive efficacy, with higher doses correlating with improved outcomes[29][33]. - The study enrolled heavily pre-treated patients, with a median of 4 prior therapies and 60% classified as refractory[28]. - CNTY-101 demonstrated an 83% overall response rate (ORR) at dose level 3B in a heavily pretreated patient population[43]. - The Phase 1 study ELiPSE-1 showed increased CNTY-101 exposure with multiple infusions, indicating extended persistence in circulation beyond day 15[36]. - CNTY-101 treatment resulted in rapid B-cell depletion observed in the first cycle, with a naive non-class switched profile of re-emergent B-cells[39]. - The Phase 1 ELiPSE-1 trial of CNTY-101 is ongoing, with updated clinical data expected for multiple malignancies[78]. - The CALiPSO-1 trial has been initiated for participants with systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (dcSSc)[80]. Safety Profile - CNTY-101's safety profile includes no instances of Graft vs Host Disease (GvHD) and manageable adverse events, such as Grade 1 and 2 cytokine release syndrome (CRS)[32]. - The study included 11 patients in Schedule A and 8 patients in Schedule B, with favorable initial safety profiles allowing outpatient delivery[43]. - CNTY-101's pharmacokinetics and pharmacodynamics are characterized by short-lived, predictable profiles, contributing to manageable safety[48]. Product Development and Pipeline - CNTY-101 incorporates six precision gene edits, including CD19-targeted CAR and safety switches, enhancing its therapeutic profile[22]. - The product pipeline includes multiple candidates, with CNTY-308 and CNTY-361 also targeting autoimmune diseases and B-cell malignancies, respectively[15]. - CNTY-308, another product in development, is an iPSC-derived CD19-targeted CAR-iT cell therapy showing comparable preclinical activity to autologous CAR-T cells[59]. - Century Therapeutics is focusing on expanding its pipeline into additional autoimmune indications, leveraging its Allo-Evasion™ technology[77]. - The differentiated pipeline includes multiple opportunities in autoimmune diseases, supported by promising preclinical data[80]. Manufacturing and Technology - The company is advancing its iPSC-derived cell types, focusing on scalable and reproducible manufacturing processes to reduce costs[5]. - The company has established in-house manufacturing capabilities, including a 53,000 ft² cGMP facility, to ensure efficient and scalable production[76]. - The iPSC Precision Engineering platform allows for precise CRISPR-mediated gene editing, reducing off-target integration and enhancing product quality[75]. - The platform enables lower cost of goods sold (COGs) compared to donor-derived or autologous therapies, enhancing batch-to-batch consistency[48]. - The company aims to manufacture at antibody-like scale, optimizing processes to maximize yield and reduce costs[76]. Financials and Future Plans - The company ended FY24 with cash and investments of approximately $2 million, noting that this estimate is unaudited and preliminary[79]. - Future development plans include progressing CNTY-101 through clinical trials and obtaining FDA clearance for IND submissions[3]. - The company is expanding clinical trial sites to the EU in 2025, following the initial enrollment in the USA[53]. - Century Therapeutics is advancing next-generation iPSC-derived NK and T cell therapy candidates for cancer treatment, with encouraging preliminary clinical data from Phase 1 trial of CNTY-101 in R/R B-cell lymphomas[77].